About: Ocriplasmin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ocriplasmin Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5AD9-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5ADA-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# FDA label (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...ugbank/indication	Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion. (en)
sameAs	Ocriplasmin
Title	Ocriplasmin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/drugbank/DB08888 http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/kegg-drug/D09646 http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/national-drug-code-directory/24856-001-00 http://linked.opendata.cz/resource/drugbank/drug/DB08888/identifier/wikipedia/Ocriplasmin
http://linked.open...mechanismOfAction	Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA). (en)
http://linked.open...drugbank/toxicity	The most commonly reported reactions (≥ 5%) in patients treated with ocriplasmin were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema. (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/52-92
foaf:page	http://www.drugs.com/jetrea.html http://www.rxlist.com/jetrea-drug.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5ADC-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5ADB-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Ocriplasmin
http://linked.open...ugbank/absorption	Because of the small dose administered (0.125 mg), ocriplasmin is not expected to be in the systemic circulation following injection. Within 30 minutes after injection, levels of ocriplasmin in the vitreous are 12 mcg/mL. 24 hours after injection, levels in the virtreous are 0.5 mcg/mL (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	1048016-9-6 (en)
http://linked.open...drugbank/category	(en)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 89 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software